Pure Bioscience, Inc.
PURE· OTC
PUREPure Bioscience, Inc.
Filed Mar 17, 2023 · 10-Q · 45 days after period end · 0001493152-23-008080
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $397.00K | $416.00K | $916.00K | $349.00K |
| Net Income | -$1.06M | -$702.00K | -$595.00K | -$666.00K |
| EPS Diluted | -$0.02 | -$0.01 | -$0.01 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
ended Jan 31, 2023 · filed Mar 17, 2023 · 45 d after period end
